1-methyl-2-[(4-methyl-1-piperidinyl)methyl]-3-indolecarbonitrile

1-methyl-2-[(4-methyl-1-piperidinyl)methyl]-3-indolecarbonitrile, also known as **MK-801** or **dizocilpine**, is a potent and selective non-competitive antagonist of the **NMDA receptor**.

**NMDA receptors** are a type of glutamate receptor crucial for learning, memory, and synaptic plasticity. They are also implicated in various neurological disorders like epilepsy, Alzheimer's disease, and stroke.

**Importance in research:**

* **Neuroscience:** MK-801 is a valuable tool for studying the role of NMDA receptors in various neurological functions and disorders. It allows researchers to:
* Investigate the mechanisms of learning and memory.
* Understand the role of NMDA receptors in neuronal development and plasticity.
* Explore the potential therapeutic effects of modulating NMDA receptor activity in neurological diseases.
* **Drug development:** MK-801 has been studied for its potential therapeutic use in conditions like:
* **Pain management:** Due to its analgesic properties.
* **Antidepressant effects:** By modulating NMDA receptor activity in the brain.
* **Neuroprotective effects:** In conditions like stroke and traumatic brain injury.
* **Experimental model:** MK-801 is widely used in animal models to study the effects of NMDA receptor blockade on various physiological and behavioral processes.

**However, MK-801 has significant side effects, including:**

* **Neurotoxicity:** Can cause brain damage and seizures.
* **Psychotomimetic effects:** Can induce hallucinations and psychosis.

Therefore, **MK-801 is not currently used clinically** due to its safety concerns. However, its research value remains significant as it provides valuable insights into the role of NMDA receptors in various neurological processes and disorders.

Ongoing research focuses on developing safer and more selective NMDA receptor modulators with potential therapeutic applications.